

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

DOE/ER/60460 - TH

Harvard-MIT Research Program in Short-lived Radiopharmaceuticals Final Report (1977-1994)

S. James Adelstein, M.D., Ph.D., Project Director

Office of Sponsored Programs
Massachusetts Institute of Technology
77 Massachusetts Avenue
Cambridge, Massachusetts 02139

February 1995

Prepared for
U. S. Department of Energy
Agreement Number DE-FG02-86ER60460 (Formerly DE-AC02-76EV04115)

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

MASTER

DISCLAIMER

**Portions of this document may be illegible
in electronic image products. Images are
produced from the best available original
document.**

This report was prepared as an account of work sponsored by the United States Government. Neither the United States nor the Department of Energy, nor any of their employees, nor any of their contractors, subcontractors, or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product or process disclosed or represents that its use would not infringe privately-owned rights.

The Harvard-MIT Research Program in Short-lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working in radiopharmaceutical chemistry at Harvard Medical School, the Massachusetts Institute of Technology, and the Massachusetts General Hospital. To this was added a group at The Children's Hospital. From these collaborations and building upon the special strengths of the participating individuals, laboratories and institutions, it was hoped that original approaches would be found for **the design of new, clinically useful, radiolabeled compounds.**

The original thrust of this proposal included: (a) examination of the coordination chemistry of technetium as a basis for rational radiopharmaceutical design, (b) development of an ultrashort-lived radionuclide generator for the diagnosis of congenital heart disease in newborns, (c) synthesis of receptor-site-directed halopharmaceuticals, (d) improved facile labeling of complex molecules with positron-emitting radionuclides. Our 1986 proposal was oriented toward organs and disease, emphasizing radiolabeled agents that delineate specific functions and the distribution of receptors in brain, heart, and tumors. In 1989, we further refined our purposes and focussed on two major aims: (a) synthesis and utilization of neutral technetium and rhenium complexes of high specific activity, and (b) development of new approaches to the radiolabeling of proteins, peptides, immunoglobulins, and their fragments. In 1992, we amended this proposal to concentrate our efforts on biologically active peptides and proteins for targeted radiodiagnosis and therapy.

A. Specific Project Objectives

The Harvard-MIT Research Program in Short-lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working in fields related to radiopharmaceutical chemistry at Harvard Medical School, the Massachusetts Institute of Technology, and the Massachusetts General Hospital. To this was added a group working at The Children's Hospital. From these collaborations and building upon the special, but different, strengths of the participating individuals, laboratories, and institutions, it was hoped that original approaches would be found for the design of new, clinically useful, radiolabeled compounds.

1. 1977-1989

The original thrust of this proposal was eclectic. Projects included: (a) an examination of the coordination chemistry of technetium as a basis for rational radiopharmaceutical design, (b) the development of an ultrashort-lived radionuclide generator for the diagnosis of congenital heart disease in newborns, (c) the synthesis of receptor-site-directed halopharmaceuticals, (d) an improved facile synthesis of complex molecules labeled with positron-emitting radionuclides. Our 1986 proposal was oriented toward organs and disease as well as the science and technology required to produce more effective radiopharmaceuticals. It emphasized agents that delineate specific functions (blood flow, metabolism) and the distribution of receptors (transmitter, hormone, immune) in brain, heart and tumors.

2. 1989-1992

In 1989, we further refined our purposes and organized our proposal around two major aims, both subsumed as the chemical basis of radiopharmaceutical action: (a) studies in technetium chemistry to develop synthesis and utilization of neutral technetium and rhenium complexes of high specific activity, and (b) development of binding-site-directed radiopharmaceuticals to radiolabel proteins, peptides, immunoglobulins and their fragments and assessment of the biologic consequences of these techniques.

3. 1992-1993 (extension to 1994)

In our 1992-1993 proposal, still retaining the chemical thrust of the research, we proposed to concentrate our efforts on the radiolabeling of biologically active peptides and proteins for targeted radiodiagnosis and therapy. The importance of biologically active peptides for a host of functions has now become clear. These molecules, of varying size and composition, play essential and specific roles as hormones, growth factors, and neurotransmitters. Their specificity derives, in part, from particular receptors found on the surface of cells that are their targets, e.g. islet cells of the pancreas, fibroblasts of wounded tissue, fields of neurons in the central nervous system. Aside from the immunoglobulin receptors, little effort has been made to explore the possibility of utilizing these specific sites for targeted radionuclide diagnosis and therapy.

We focussed attention on methods for labeling peptides with single-photon- and annihilation-photon-emitters, testing their effectiveness in appropriate biologic models. The labeling of peptides with trace levels of technetium for diagnosis or rhenium for therapy is a formidable process. First, stable complexes of the transition elements with the peptide must be formed. Second, this must not

interfere with the distribution and binding of the peptide or, alternatively, of its labeled antagonist. Davison and Jones proposed to accomplish this by labeling the N-terminal end of peptides which is relatively inert in biologic functioning. Initially they planned to explore the use of N_2S_2 complexes with which they already had considerable experience. Fischman and Strauss proposed to continue experiments with chemotactic peptides conjugated at the C-terminal end to hydrazinonicotinamide. These conjugates, which bind specifically to chemotactic leukocytes, were to be labeled with ^{99m}Tc and used to localize sites of inflammation and infection. Elmaleh proposed to label the chemotactic peptide with the positron emitters ^{18}F and ^{124}I . The fluorine label was to be attached by way of an activated aromatic tetraalkylammonium ester or through the synthesis of a fluorocyclohexyl derivative. Kassis proposed to continue work with immunoglobulins and immunoglobulin fragments, developing indirect methods for radiolabeling antibodies and in-vitro and in-vivo techniques for assessing the immunocompetence of these radiopharmaceuticals.

B. Relationship to DOE Mission

This project was supported by the Department of Energy, Office of Energy Research, under the Office of Health and Environmental Research, Division of Medical Applications and Biophysical Research. The proposal addresses the second area of the program objectives: "the nuclear medicine component that is aimed at enhancing the beneficial applications of radiation, radionuclides, and stable isotopes in the diagnosis, study, and treatment of human diseases." It has fostered basic and applied studies for the development of radioactive agents for use in both the diagnosis and the treatment of disease and the understanding of human disorders. The research has been motivated by the recognition that diagnostic imaging is a sensitive and powerful technique for examining physiologic and pathologic processes in man. Moreover, increased knowledge in the design of binding-site-directed radiopharmaceuticals has suggested their potential application in cancer therapy. This proposal has been designed to combine the fruits of modern biologic research with nuclear technology for these purposes.

C. Relationship to Other DOE-Funded Projects

Alun G. Jones and Alan Davison, two of the investigators on Project 1, were partially supported from 01/87 to 01/90 (extended to 06/91 without funding) by DOE, DE-FG02-87ER60526, A New Approach to the Analysis of Radiopharmaceuticals. The grant was designed to investigate the application of specific techniques to radiopharmaceutical chemistry, including various forms of mass spectrometry, ^{99}Tc NMR and resonance Raman spectroscopy. The research funded represents the development of an analytical base for this (DE-FG02-86ER60460) and other grants.

D. Results

1. 1977-1989

Studies in Technetium Chemistry - to facilitate the design of radiopharmaceuticals incorporating technetium-99m

- a. first identification and characterization of oxotechnetium(V) complexes isolated from aqueous solution
- b. elucidation of the systematics in technetium complexation
- c. first application of high resolution field desorption mass spectroscopy to the structure of these complexes
- d. design and synthesis of new agents for heart, brain, and kidney imaging based on the chemistry of the element; n.b. isonitriles for cardiac imaging with SPECT
- e. development of new classes of cationic and neutral complexes
- f. determination that the uptake of $Tc(AcAc)_3$ complexes by the brain has a maximum that depends on lipophilicity

Binding-Site-Directed Radiopharmaceuticals - to improve the specificity or image quality and to decrease the radiation dose through the use of short-lived and disease-specific radiopharmaceuticals

- a. preparation of radioiodinated vinylestradiol derivatives with high affinity for estrogen sites, having clinical application for detection of mammary tumors
- b. synthesis of adrenergic neuron indicators of the phenylpiperazinium type that can be labeled with either ^{123}I or ^{11}C
- c. development of novel cerebral perfusion imaging agents based on phenylpiperazines and phentermines labeled with either ^{123}I or ^{11}C
- d. development of radiohalodestannylation as a method for rapid and efficient site-specific incorporation of radioiodine and radiobromine
- e. radiolabeling of insulin with ^{123}I for biokinetic studies and preparation of high-specific-activity ^{123}I [Tyr-A14] for evaluation in human studies
- f. determination that in-vitro radioimmunoassay does not necessarily predict in-vivo behavior of a radiolabeled antibody

Osmium-191--Iridium-191m Radionuclide Generator - to decrease the radiation dose through the use of short-lived radiopharmaceuticals

development to the level of clinical utility of the $^{191}Os-^{191m}Ir$ generator for use in first pass and continuous infusion radionuclide angiography

Labeling of Complex Molecules with Fluorine-18, Nitrogen-13 and Carbon-13 - to provide short-lived, positron-emitting radiopharmaceuticals with advantages in transverse-section imaging of regional physiologic processes

- a. construction of a semiautomated modular system for preparation of reactive intermediates such as $^{11}CO_2$, $^{11}CH_2O$ and $^{11}CH_3I$
- b. development and construction of a target box for production of $^{18}F^-$ and $^{18}F_2$
- c. synthesis of a new series of ^{11}C and radioiodinated branched-chain fatty acids

- d. for myocardial and metabolic imaging improvement of $^{13}\text{NH}_3$ production and its use as an intermediate for preparation of ^{13}N -labeled amino acids such as ^{13}N -L-glutamate (enzymatic synthesis) and ^{13}N -L-asparagine (chemical synthesis) for heart and tumor imaging
- e. development of a chemical synthesis of ^{11}C -L-methionine for studying tumor growth and response to radiation therapy
- f. synthesis of ^{18}F -labeled sugar analogs, 2-[^{18}F]fluoro-2-deoxy-D-glucose and 3-[^{18}F]fluoro-2-deoxy-D-glucose, for studying brain and heart energy metabolism

2. **1989-1992**

References in parentheses refer to papers not yet submitted to the Department of Energy and, therefore, included in alphabetical order in the appendix.

Studies in Technetium Chemistry - to develop synthesis and utilization of neutral technetium and rhenium complexes of high specific activity

- a. characterization of N_2S_2 chelates; attachment of metal chelates to a progestin skeleton and conversion to oxo-rhenium complexes; assessment of diastereoisomers indicating two anti diastereomers and the syn mixture of the $11\beta\text{-N}_2\text{S}_2$ system have high affinity for the progesterone receptor suggesting potential as imaging agents for steroid-positive tumors (DiZio, Fiaschi, Davison, Jones, Katzenellenbogen, 1991)
- b. studies with human tumor cell lines and the cation $^{99\text{m}}\text{Tc}$ -hexakis(2-methoxyisobutylisonitrile) (MIBI) demonstrating that uptake is a temperature- dependent process restricted to living cells and is sensitive to changes in cytosolic and mitochondrial membrane potentials (Delmon-Moingeon, Piwnica-Worms, Van den Abbeele et al, 1990)
- c. characterization in cultured chick heart cells of the accumulation of various cationic and neutral technetium complexes indicating that cationic Tc complexes (e.g. MIBI) are taken up by mitochondria with modest washout rates and uptake is sensitive to changes in membrane potential, while neutral complexes (e.g. boronic acid adducts of technetium tris(dioxime)) are taken up by nonspecific hydrophobic partitioning with rapid biexponential washout and uptake is only slightly influenced by metabolic or cationic membrane transport inhibitors (Kronauge, Chiu, Cone et al, 1992)
- d. synthesis and identification of technetium(I) hexakis(isonitrile) complex $\text{Tc}(\text{CPI})$ containing functionalized alkyl isocyanide ligands with a terminal methyl ester group and characterization of its hydrolysis products (Kronauge, Davison, Roseberry et al, 1991); pharmacokinetic properties of this compound including rapid clearance from the lung and liver and moderate washout from heart muscle suggest potential as a myocardial imaging agent

with use in same-day stress/rest imaging protocols; examination in human volunteers and guinea pigs of its pharmacokinetics by dynamic SPECT imaging and HPLC analysis of blood samples indicate that enzymatic hydrolysis of the terminal ester group occurs in blood at a moderate rate producing new species not accumulated in heart tissue and that after extraction by the heart, liver and kidneys the Tc(CPI) complex undergoes metabolism at a slower rate giving different products suggesting a different mechanism of hydrolysis (Kronauge, Leon, Silvia Verdera et al, 1992)

- e. synthesis and characterization of new Tc(V) phenylimido complexes $[\text{TcCl}_3(\text{NPh})(\text{PPh}_3)_2]$ and $[\text{TcCl}_3(\text{NPh})(\text{Ph}_2\text{PCH}_2\text{CH}_2\text{PPh}_3)]$ as part of an ongoing project to examine organohydrazines as ligands for Tc and Re (Nicholson, Davison, Jones, 1991; Nicholson, Storm, Davis, Davison, Jones, 1992)

Binding-Site-Directed Radiopharmaceuticals - to elaborate new approaches to the radiolabeling of proteins, peptides, immunoglobulins and their fragments and to assess the biologic consequences of these techniques

- a. demonstration that preadsorption of radiolabeled antibodies to liver and spleen tissues results in significantly decreased uptake in certain normal tissues and higher tumor-to-normal-tissue ratios and that protection of the antigen-binding site during radioiodination leads to improved immunoreactivity
- b. development of indirect radiolabeling methods for monoclonal antibodies including biotinyl-m-[¹²⁵I]iodoaniline (Khawli, Kassis, 1992) and N-(m-[¹²⁵I]iodophenyl)maleimide (Khawli, Van den Abbeele, Kassis, 1992)
- c. development of a simple remote system for high-level radioiodination of monoclonal antibodies (Weadock, Anderson, Kassis, 1989) and an immunoradiometric assay for antibodies recognizing antigenic gangliosides (Baranowska-Kortylewicz, Berman, Kaldany, Eisenbarth, Kassis, 1990)
- d. demonstration that incubation of ¹²⁵I-3G5 (an IgM monoclonal antibody against a membrane ganglioside on RINm5F cells) with rat insulinoma RINm5F cell monolayers leads to cell-bound radioactivity detectable within 10 min, with electron microscopy over time confirming the presence of radiolabeled antibody on the plasma membrane followed by distinct capping and diffuse radioactive deposits within the cells (Mariani, Ito, Nayak et al, 1991)
- e. involvement in two on-going clinical studies: phase I therapeutic trial examining the feasibility of intraperitoneal radioimmunotherapy in refractory ovarian carcinoma utilizing escalating doses of ¹³¹I labeled OC125 F(ab')₂ (Muto, Finkler, Kassis, Lepisto, Knapp, 1990; Muto, Finkler, Kassis et al, 1992), and detection of focal infection with ¹¹¹In-human polyclonal IgG
- f. improvement of methods for labeling peptides and proteins with ¹⁸F, including reductive alkylation with the use of tetrafluorophenyl and pentafluorophenyl esters (Herman, Elmaleh, Fischman, Hanson, Strauss

1991; Shen, Hanson, Elmaleh, 1991)

- g. demonstration that multiple PET measurements can be used to assess pharmacokinetics of fluconazole labeled with ^{18}F in rabbits; direct measurement of partition coefficient in muscle agrees closely with predictions of kinetic model hypothesizing that compound is compartmentalized in blood and tissue with rate constants describing transition between compartments (Fischman, Alpert, Livni et al, 1991)
- h. characterization of uptake and retention of tritiated tetraphenylphosphonium in certain human and animal nervous-system-tumor cell lines demonstrating that certain of these tumors retain lipophilic compounds with a decentralized positive charge which may be useful in the intraoperative delineation of tumor margins and in photodynamic therapy (Steichen, Weiss, Elmaleh, Martuza, 1991)
- i. characterization and comparison of various radiolabeled proteins for detection of focal sites of infection using rat and rabbit *E. coli*, soft-tissue infection models: demonstration that $^{99\text{m}}\text{Tc}$ -labeled monoclonal antigranulocyte antibody and ^{111}In -labeled IgG are equivalent, nonimmunogenic agents (Juveid, Fischman, Rubin, Baum, Strauss, 1991), and ^{111}In -labeled IgG and ^{125}I -labeled albumin accumulation are not significantly different indicating binding of IgG to Fc receptors on inflammatory cells is not its mechanism of localization in infection (Tompkins, Fischman, Yarmush, 1991)
- j. conformational studies of the endogenous brain peptide N-Tyr-MIF-1 in aqueous solution by ^1H nuclear magnetic resonance spectroscopy as a basis for designing new analogs (Petersheim, Moldow, Halladay, Kastin, Fischman, 1992)

Completion of Work Begun During 1977-1989 Funding Period

- a. assessment of potential clinical utility of fatty acid imaging and comparison of ^{11}C and ^{123}I labeled straight-chain and branched-chain fatty acids using PET and single photon imaging, respectively (Fischman, Saito, Dilsizian et al, 1989)
- b. demonstration in mouse myocardium by microautoradiography and electron microscopy that ^3H -beta-methylheptadecanoic acid is found in mitochondria and lipid droplets and by thin-layer chromatography that ^{14}C -beta-methylheptadecanoic acid is found in various lipid pools, indicating distribution similar to physiologic fatty acids (Livni, Ito, Kassis, Elmaleh, 1990)

3. 1992-1993 (extension to 1994)

Studies in Technetium Chemistry - to develop synthesis and utilization of neutral technetium and rhenium complexes of high specific activity

- a. evaluation of pharmacokinetics of $^{99\text{m}}\text{Tc}$ -CPI in isolated contractile rat atrial

tissue demonstrating temperature-sensitive and concentration-dependent linear accumulation over time and slow washout with 75% of the retained activity the original Tc-CPI complex (Vedera, Leon, Kronauge et al, 1993)

- b. development of a method for labeling peptides/ proteins by introducing N_2S_2 chelates that possess amine amide dithiols as the coordinating atoms; use of this method with a final N-alkylation at the amino nitrogen for conjugation to other molecules of interest; complexation with Tc or Re by using pertechnetate or perrhenate with trityl-protected ligands and $SnCl_2\text{-HCl}$ as the reducing agent or alternatively by deprotection of the thiols followed by complexation with prereduced metal oxo precursors (Mahmood, Wolff, Davison, Jones, in press)
- c. development of a method using hydrophilic, polycationic poly-D-lysine modified by N-acetyl homocysteine thiolactone with high affinity for reduced Tc to label white blood cells (Mahmood, Delmon-Moingeon, Limpa-Amara, Davison, Jones, 1993; Mahmood, Delmon-Moingeon, Limpa-Amara, Davison, Jones, 1994; Mahmood, Delmon-Moingeon, Limpa-Amara, Davison, Jones, submitted); evaluation of integrity and immune functions of lymphocytes labeled with this carrier indicating radiolabeling procedure does not alter these characteristics (Delmon-Moingeon, Mahmood, Davison, Jones, submitted)

Binding-Site-Directed Radiopharmaceuticals - to elaborate new approaches to the radiolabeling of proteins, peptides, immunoglobulins and their fragments and to assess the biologic consequences of these techniques

- a. synthesis and evaluation of hydrazinonicotinamide-derivatized chemotactic peptide analogs labeled by ^{99m}Tc -glucoheptonate (^{99m}Tc -HP): demonstration that ^{99m}Tc -HP maintain biologic activity and receptor binding when assayed in human leukocytes; assessment in *E. coli*, soft-tissue models of infection indicating ^{99m}Tc -HP are cleared rapidly from blood in rats with low levels of accumulation in normal tissues and produce good images of infection sites in rabbits at 15 hours (Babich, Solomon, Pike et al, 1993); assessment in rhesus monkeys indicating that ^{99m}Tc -HP induce significant transient reductions in peripheral leukocyte levels only at high peptide doses, and that in rhesus monkeys with focal sites of mild sterile inflammation good target/nontarget ratios are achieved at 3 hours (Fischman, Rauh, Solomon et al, 1993); comparison of one ^{99m}Tc -HP with ^{111}In -leukocytes (WBC) in rabbits demonstrating that the ^{99m}Tc -labeled compound achieves better absolute levels of accumulation and target/nontarget ratios at all imaging times (Babich, Graham, Barrow et al, 1993)
- b. development of a method for labeling immunoglobulins with bifunctional, sulfhydryl-selective, and photoreactive coumarins (Baranowska-Kortylewicz, Kassis, 1993)
- c. development of a semipreparative isoelectrophoresis method for separating antibody isoforms and DTPA-antibody conjugates on the basis of pI,

permitting isolation of antibody isoform fractions from immunologically irrelevant and low-affinity antibodies (Gangopadhyay, Saravis, Van den Abbeele, Kassis, in press) and DTPA-antibody isoform fractions with desired numbers of DTPA and specific negative charges without a measurable diminution in immunoreactivity (Gangopadhyay, Saravis, Kassis, 1994)

- d. determination that radioiodination changes the pI of proteins differentially depending on the oxidant used and its concentration, and that changes in electrophoretic mobility are a function of the iodide/protein ratio (Gangopadhyay, Van den Abbeele, Kassis, 1994)
- e. rapid synthesis of N-(4-[^{127/125/123}I]iodobenzyl) biotin amides via the trazine of N-(4-aminobenzyl)biotin amide to produce a high specific activity, biochemically intact biotin molecule (Kortylewicz, Baranowska-Kortylewicz, Adelstein, Carmel, Kassis, 1994)
- f. development of a one-step method for radiolabeling proteins using pentafluorophenyl derivatives and tetrabutylammonium [¹⁸F]fluoride exchange (Herman, Fischman, Tompkins et al, 1994)
- g. preparation of ¹⁸F-labeled biotin derivatives in high specific activity for PET applications: achievement of infection localization in *E. coli*-infected rats less than 1 hour after injection (Shoup, Fischman, Jaywook et al, 1994)

Completion of Work Begun During 1977-1989 Funding Period

- a. synthesis and evaluation of 1-[¹¹C]methyl-4-aryl-piperazinium salts as myocardial imaging agents; biodistribution studies in rats and imaging in dogs indicating high concentrations in heart obtained at 5 min and level of activity at 20 min maintained over 1-hour period (Elmaleh, Padmanabhan, Hassan et al, 1993)
- b. preparation of a series of phentermine analogs including the unsubstituted, para-F, -Cl, -Br and -I, and the meta-CF₃, their [¹¹C]methylation, and evaluation in rats to determine structure-localization relationships for cerebral blood-flow imaging; N-[¹¹C]methyl-p-iodophentermine with best biodistribution (Elmaleh, Kizuka, Hanson et al, 1993); method for rapid preparation of N-[¹¹C-methyl]-chlorphentermine (Kizuka, Elmaleh, 1993)
- c. determination of rates of fatty acid metabolism in a dog myocardium model from steady-state concentration of 1-[¹¹C]betamethylheptadecanoic acid (Elmaleh, Livni, Alpert et al, 1994)

E. Project Output: Complete List of Publications Supported Completely or Partially by DE-FG02-86ER60460 (Formerly DE-AC02-76EV04115)

1977

Bloomer WD, Adelstein SJ. 5-¹²⁵I-Iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. *Nature* 1977; 265:620-621.

Bloomer WD, Adelstein SJ. Therapeutic application of iodine-125 labeled iododeoxyuridine in an

early ascites tumour model. *Curr Top Radiat Res Q* 1977; 12:513-525.

Hnatowich DJ, Kulprathipanja S, Treves S. An improved ^{191}Os - $^{191\text{m}}\text{Ir}$ generator for radionuclide angiography. *Radiology* 1977; 123:189-194.

Kulprathipanja S, Hnatowich DJ, Davis MA, Treves S. Radionuclide angiography with iridium-191m ($T_{1/2} = 4.9$ sec). An improved osmium-191-iridium 191m generator. In: *Medical Radionuclide Imaging*, Vol II. Vienna: IAEA, 1977:53-59.

Kulprathipanja S, Hnatowich DJ, Treves S. The hydrolysis and radiolysis of ^{191}Os hexachloroosmate(IV). *J Inorg Nucl Chem* 1977; 39:933-935.

1978

Bloomer WD, Adelstein SJ. 5-(^{125}I)-Iododeoxyuridine in experimental tumor therapy. In: Spencer RP, ed. *Therapy in Nuclear Medicine*. New York: Grune and Stratton, 1978:177-183.

Bloomer WD, Adelstein SJ. 5-(^{125}I)-Iododeoxyuridine and the Auger effect: Biological consequences and implications for therapy. *Pathobiol Annu* 1978; 8:407-421.

DePamphilis BV, Jones AG, Davis MA, Davison A. The preparation and crystal structure of oxotechnetiumbis(thiomercaptoacetate) and its relationship to radiopharmaceuticals labeled with $^{99\text{m}}\text{Tc}$. *J Am Chem Soc* 1978; 100:5570-5571.

Hanson RN, Holman BL, Davis MA. Synthesis and biologic distribution of radioiodinated beta adrenergic antagonists. *J Med Chem* 1978; 21:830-833.

Holman BL, Harris GI, Neirinckx RD, Jones AG, Idoine J. Tantalum-178. A shortlived isotope for nuclear medicine: Production of the parent ^{178}W . *J Nucl Med* 1978; 19:510-513.

Jacobs PM, Davis MA. Novel synthesis of 2-selenienylalanine. *J Org Chem* 1978; 44:178-179.

Neirinckx RD, Jones AG, Davis MA, Harris GI, Holman BL. Tantalum-178. A shortlived isotope for nuclear medicine: Development of a potential generator system. *J Nucl Med* 1978; 19:514-519.

Neirinckx RD, Jones AG, Davis MA, Holman BL. A ^{178}W - ^{178}Ta generator system. In: Woldring M, Schmidt HAE, eds. *Nuklear Medizin - Stand und Zukunft*, Proceedings 15th Annual Meeting, European Society of Nuclear Medicine. Stuttgart: FK Schattauer, 1978:241-244.

1979

DePamphilis BV, Jones AG, Davis MA, Davison A. Preparation of a new oxotechnetium(V)-sulfur complex. In: Sodd VJ, Hoogland DR, Allen DR, Ice RD, Sorensen JA, eds. *Radiopharmaceuticals II: Proceedings, Second International Symposium on Radiopharmaceuticals*. New York: The Society of Nuclear Medicine, 1979:155-161.

Elmaleh DR, Hnatowich DJ, Kulprathipanja S. A novel synthesis of ^{13}N -L-asparagine. *J Labelled Compd Radiopharm* 1979; 16:92-93.

Hanson RN, Davis MA. Potential adrenal imaging agents: Synthesis and biodistribution of 1,2,3-selenadiazoles. *J Labelled Compd Radiopharm* 1979; 16:31-32.

Hanson RN, Holman BL, Davis MA. ^{125}I -labeled 1-(2'-acetyl-4'-[orthoiodobenzoyl]aminophenoxy)-3-isopropylaminopropan-2-ol. *J Labelled Compd Radiopharm* 1979; 16:269-273.

Hnatowich DJ, Kulprathipanja S, Evans G, Elmaleh DR. A comparison of positron emitting blood

pool imaging agents. *Int J Appl Radiat Isot* 1979; 30:335-340.

Holman BL, Davis MA, Hanson RN. Radioiodinated beta adrenergic antagonists as potential myocardial imaging agents. *J Labelled Compd Radiopharm* 1979; 16:69-71.

Kulprathipanja S, Hnatowich DJ, Beh R, Elmaleh D. Formation constants of gallium- and indium-transferrin. *Int J Nucl Med Biol* 1979; 6:138-141.

Neirinckx RD, Ku TH, Holman BL, Jones AG, Richards P. Production and purification of tungsten-178. *Int J Appl Radiat Isot* 1979; 30:341-343.

Ritz J, Neirinckx RD, Jones AG, Davis MA. Lymphocyte labeling with ^{111}In : The effect on labeled cells. *J Labelled Compd Radiopharm* 1979; 16:232-233.

Trop HS, Davison A, Carey GH, DePamphilis BV, Jones AG, Davis MA. Electrochemical studies on halide and pseudo-halide complexes of technetium and rhenium. *J Inorg Nucl Chem* 41:271-272.

Wilson BW, Costello CE, Carr SA, Biemann K, Orvig C, Davison A, Jones AG. Field desorption mass spectrometry of complex anions containing rhenium and technetium. *Anal Lett* 1979; 12(A3):303-311.

1980

Bloomer WD, McLaughlin WH, Weichselbaum RR, Tonnesen GL, Hellman S, Seitz DE, Hanson RN, Adelstein SJ, Rosner AL, Burstein NA, Nove JJ, Little JB. Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. *Int J Radiat Biol* 1980; 38:197-202.

Brownell GL, Ackerman RH, Strauss HW, Elmaleh DR, Cochavi S, Alpert NM, Correia JA, Kefratt KJ, Taveras J. Preliminary imaging results with ^{18}F -2-fluoro-2-deoxy-D-glucose. *J Comput Assist Tomogr* 1980; 4:473-477.

Cheng C, Treves S, Samuel A, Davis MA. A new osmium-191-iridium-191m generator. *J Nucl Med* 1980; 21:1169-1176.

Davison A, Orvig C, Trop HS, Sohn M, DePamphilis BV, Jones AG. The preparation of oxobis-(thiolato) complexes of technetium(V) and rhenium(V). *Inorg Chem* 1980; 19:1988-1992.

Elmaleh DR, Hnatowich DJ, Cochavi S, McKusick KA, Brownell GL, Strauss HW. Emission tomographic images of the skull with fluorine-18. *Int J Nucl Med Biol* 1980; 7:289-293.

Hanson RN, Davis MA. Selenium-sulfur analogs 2. Synthesis and characterization of 4-alkyl-1,2,3-selenadiazoles and -1,2,3-thiadiazoles. *J Heterocycl Chem* 1980; 17:1245-1247.

Jones AG, Orvig C, Trop HS, Davison A, Davis MA. A survey of reducing agents for the synthesis of tetraphenylarsonium oxotechnetiumbis(ethanedithiolate) from [$^{99\text{m}}\text{Tc}$] pertechnetate in aqueous solution. *J Nucl Med* 1980; 19:279-281.

Seitz DE, Tonnesen GL, Hellman S, Hanson RN, Adelstein SJ. Iododestannylation. Position-specific synthesis of iodotamoxifen. *J Organomet Chem* 1980; 186:C33-C36.

Treves S, Cheng C, Samuel A, Lambrecht R, Babchick B, Zimmerman R, Norwood W. Iridium-191m angiography for the detection and quantitation of left-to-right shunting. *J Nucl Med* 1980; 21:1151-1157.

Trop HS, Davison A, Jones AG, Davis MA, Szalda DJ, Lippard SJ. Synthesis and physical properties of hexakis(isothiocyanato)technetate(III) and -(IV) complexes: Structure of the

[Tc(NCS)₆]³⁻ ion. Inorg Chem 1980; 19:1105-1110.

Trop HS, Jones AG, Davison A. Technetium cyanide chemistry: Synthesis and characterization of technetium(III) and -(V) cyanide complexes. Inorg Chem 1980; 19:1993-1997.

1981

Bloomer WD, Adelstein SJ. Iodine-125 cytotoxicity: Implications for therapy and estimation of radiation risk. Int J Nucl Med Biol 1981; 8:171-178.

Bloomer WD, McLaughlin WH, Neirinckx RD, Adelstein SJ, Gordon PR, Ruth TJ, Wolf AP. Astatine-211-tellurium radiocolloid cures experimental malignant ascites. Science 1981; 212:340-341.

Bloomer WD, McLaughlin WH, Weichselbaum RR, Hanson RN, Adelstein SJ, Seitz DE. The role of subcellular localization in assessing the cytotoxicity of iodine-125 labeled iododeoxyuridine, iodotamoxifen, and iodoantipyrine. J Radioanal Chem 1981; 65:209-221.

Bottaro JC, Hanson RN, Seitz DE. Simple and direct synthesis of trans-1,2-bis-(tri-n-butylstannyly)ethylene. J Org Chem 1981; 46:5221-5222.

Davison A, Jones AG, Abrams MJ. New 2,2'-bipyridine and 1,10-phenanthroline oxohalide complexes of technetium(VII) and (V). Inorg Chem 1981; 20:4300-4302.

Davison A, Jones AG, Muller L, Tatz R, Trop HS. Synthesis and characterization of oxopenta-(isothiocyanato)metallate(V) complexes of rhenium and technetium. Inorg Chem 1981; 20: 1160-1163.

DePamphilis BV, Orvig C, Jones AG, Davison A. A new type of oxotechnetium(V) complex. J Labelled Compd Radiopharm 1981; 18:146-147.

Elmaleh DR, Goodman MM, Kefkott KJ, Correia JA, Alpert NM, Varnum DA, Ackerman RH, Strauss HW, Brownell GL. ¹⁸F sugar analog for studies of tissue metabolism. In: Medical Applications of Cyclotrons II. Proceedings Second Symposium on Medical Applications of Cyclotrons, 1981, Turku, Finland. Turku: University of Turku, 1981:153-155.

Elmaleh DR, Kefkott KJ, Goodman MM, Varnum DA, Lade R, Ackerman RH, Strauss HW, Brownell GL. A comparison of ¹⁸F sugar analogs in animals. In: Medical Applications of Cyclotrons II. Proceedings Second Symposium on Medical Applications of Cyclotrons, 1981, Turku, Finland. Turku: University of Turku, 1981:156-160.

Goodman MM, Elmaleh DR, Kefkott KJ, Ackerman RH, Hoop B Jr, Brownell GL, Alpert NM, Strauss HW. ¹⁸F-labeled 3-deoxy-3-fluoro-D-glucose for the study of regional metabolism in the brain and heart. J Nucl Med 1981; 22:138-144.

Hanson RN, Blumberg JB, Poddubiuk ZM, Davis MA, Holman BL. Preparation and biodistribution of a ¹²⁵I-labeled β -adrenoceptor antagonist bearing a cardioselectivity-enhancing N-substituent. Int J Appl Radiat Isot 1981; 32:429-433.

Hanson RN, Davis MA. Radiolabeled enzyme inhibitors as potential adrenal imaging agents. J Labelled Compd Radiopharm 1981; 18:49.

Hanson RN, Davis MA. Selenium-sulfur analogs III. Synthesis and biodistribution of two ⁷⁵Se-labeled 4-substituted-1,2,3-selenadiazoles. J Pharm Sci 1981; 70:91-93.

Hanson RN, Davis MA. Selenium-sulfur analogs 4. Synthesis and characterization of (\pm)- β -(2-amino-1,3-selenazol-4-yl)alanine. J Heterocycl Chem 1981; 18:205-206.

Hanson RN, Seitz DE. Synthesis and evaluation of 17- α -[¹²⁵I]iodovinylestradiol: A potential estrogen receptor radioligand. *Trans Am Nucl Soc* 1981; 39:32-33.

Hanson RN, Seitz DE, Tonnesen GL. Preparation and biodistribution of the antiestrogen [¹²⁵I]-iodotamoxifen. *J Labelled Compd Radiopharm* 1981; 18:99.

Hanson RN, Tonnesen GL, McLaughlin WH, Bloomer WD, Seitz DE. Electrophilic radioiodo-destannylation as a new radioiodination method. *J Labelled Compd Radiopharm* 1981; 18:128-129.

Jham GN, Hanson RN, Giese RW, Vouros P. Selenium-sulfur analogs: Mass spectrometric comparison of thiazoles and selenazoles. *J Heterocycl Chem* 1981; 13:35-1340.

Kaplan WD, Bloomer WD, Jones AG, Federschneider J, Knapp RC. Mediastinal lympho-scintigraphy in ovarian cancer using intraperitoneal autologous technetium-99m labeled erythrocytes. *Br J Radiol* 1981; 54:126-131.

Kaplan WD, Zimmerman RE, Bloomer WD, Knapp RC, Adelstein SJ. Therapeutic intraperitoneal ³²P: A clinical assessment of the dynamics of distribution. *Radiology* 1981; 138:683-688.

Tonnesen GL, Hanson RN, Seitz DE. Position-specific radioiodination utilizing an aryltributylstannyl intermediate: Synthesis of ¹²⁵I-iodotamoxifen. *Int J Appl Radiat Isot* 1981; 32:171-173.

Treves S, Cheng C, Samuel A, Fujii A, Lambrecht R. Detection and quantitation of left-to-right shunting by iridium-191m angiography. In: *Medical Radionuclide Imaging* 1980, Vol II. Vienna: IAEA, 1981:231-241.

Trop HS, Davison A, Jones AG. The synthesis and characterization of (n-Bu₄N)₃Re(NCS)₆, a rhenium(III) thiocyanate complex. *Inorg Chim Acta Lett* 1981; 54:L61-L62.

1982

Bloomer WD, Adelstein SJ. Therapeutic applications of Auger and alpha emitting radionuclides. *Radioakt Isot Klin Forsch* 1982; 15:227-234.

Bloomer WD, Adelstein SJ. Radiation toxicology. In: Tu AT, ed. *Survey of Contemporary Toxicology* Vol 2. New York: Wiley-Interscience, 1982:37-85.

Bloomer WD, McLaughlin WH, Adelstein SJ. Therapeutic implications of iodine-125 cytotoxicity. *Int J Radiat Oncol Biol Phys* 1982; 8:1903-1908.

Bloomer WD, McLaughlin WH, Adelstein SJ, Wolf AP. Therapeutic applications of Auger and alpha emitting radionuclides. In: Raynaud C, ed. *Nuclear Medicine and Biology*, Proceedings Third World Congress of Nuclear Medicine and Biology, Paris, August 1982, Vol I. Paris: Pergamon Press, 1982:147-150.

Cheng C, Treves S, Samuel A. A new ¹⁹¹Os-^{191m}Ir radionuclide generator for first pass angiography. In: Lambrecht RM, Marcos N, eds. *Applications of Nuclear and Radiochemistry*. Elmsford: Pergamon Press, 1982:73-87.

Hanson RN. Radioiodinated 1-carboxamidino-4-phenylpiperazine: A potential adrenal and myocardial imaging radiopharmaceutical. *Int J Appl Radiat Isot* 1982; 33:629-632.

Hanson RN. Radioiodinated 1-substituted-4-phenylpiperazines: Potential myocardial imaging agents. *J Labelled Compd Radiopharm* 1982; 13:03-1304.

Hanson RN, Seitz DE. Radioiododestannylation: A new method for specifically labeled

radiopharmaceuticals. *J Labelled Compd Radiopharm* 1982; 19:1585-1586.

Hanson RN, Seitz DE. Tissue distribution of the radiolabeled antiestrogen [^{125}I]iodotamoxifen. *Int J Nucl Med Biol* 1982; 9:105-107.

Hanson RN, Seitz DE. Estrogen receptor seeking radiopharmaceuticals: 17α -Iodoxyl and iodoaryl estradiols. In: Raynaud C, ed. *Nuclear Medicine and Biology, Proceedings Third World Congress of Nuclear Medicine and Biology*, Paris, August 1982, Vol IV. Paris: Pergamon Press, 1982:3200-3203.

Hanson RN, Seitz DE, Bottaro JC. $\text{E}-17\alpha-[^{125}\text{I}]$ iodovinylestradiol: An estrogen-receptor-seeking radiopharmaceutical. *J Nucl Med* 1982; 23:431-436.

Levy S, Elmaleh DR, Livni E. A new method using anhydrous [^{18}F]fluoride to radiolabel 2-[^{18}F]fluoro-2-deoxy-D-glucose. *J Nucl Med* 1982; 23:918-922.

Livni E, Elmaleh DR, Levy S, Brownell GL, Strauss HW. Beta-methyl-[$1-^{11}\text{C}$]heptadecanoic acid: A new myocardial metabolic tracer for positron emission tomography. *J Nucl Med* 1982; 23:169-175.

Treves S, Fujii A, Cheng C, Kuruc A. Iridium-191m radionuclide angiography: Detection and quantitation of left-to-right shunts. In: Raynaud C, ed. *Nuclear Medicine and Biology, Proceedings Third World Congress of Nuclear Medicine and Biology*, Paris, August 1982, Vol IV. Paris: Pergamon Press, 1982:2732-2736.

Treves S, Fyler D, Fujii A, Kuruc A. Low radiation iridium-191m radionuclide angiography: Detection and quantitation of left-to-right shunts in infants. *J Pediatr* 1982; 101:210-213.

1983

Abrams MJ, Davison A, Jones AG, Costello CE, Pang H. The synthesis and characterization of hexakis(alkylisocyanide) and hexakis(aryliscyanide) complexes of technetium(I). *Inorg Chem* 1983; 22:2798-2800.

Bloomer WD, McLaughlin WH, Milius RA, Weichselbaum RR, Adelstein SJ. Estrogen receptor-mediated cytotoxicity using iodine-125. *J Cell Biochem* 1983; 21:39-45.

Davison A. The coordination chemistry of technetium. In: Deutsch E, Nicolini M, Wagner HN Jr, eds. *Technetium in Chemistry and Nuclear Medicine*. Verona: Cortina International, 1983:3-14.

DePamphilis BV, Jones AG, Davison A. Ligand reactivity patterns of oxotechnetium(V) complexes. *Inorg Chem* 1983; 22:2292-2297.

Elmaleh DR, Livni E, Levy S, Varnum D, Strauss HW, Brownell GL. Comparison of ^{11}C - and ^{14}C -labeled fatty acids and their β -methyl analogs. *Int J Nucl Med Biol* 1983; 10:181-187.

Goodman MM, Knapp FF, Elmaleh DR, Strauss HW. New myocardial imaging agents: Synthesis of 15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid by the decomposition of piperidinyltriazene precursor. *J Org Chem* 1983; 49:2322-2325.

Hanson RN. Preparation and evaluation of radioiodinated phenylpiperazines as adrenomedullary imaging agents. *Int J Nucl Med Biol* 1983; 10:219-222.

Jones GS, Hanson RN, Davis MA. Selenium-sulfur analogs 6. Selenoisosteres of levamisole. *J Heterocycl Chem* 1983; 20:523-526.

Kuruc A, Treves S, Parker JA. Accuracy of deconvolution algorithms assessed by simulation

studies: Concise communication. *J Nucl Med* 1983; 24:258-263.

Kuruc A, Treves S, Parker JA, Cheng C, Sawan A. Radionuclide angiography: An improved deconvolution technique for improvement after suboptimal bolus injection. *Radiology* 1983; 148:233-238.

Levy S, Livni E, Elmaleh DR, Varnum DA, Brownell GL. 2-Deoxy-2-[¹⁸F]fluoro-3-*o*-methyl-D-glucose synthesis and animal biodistribution studies. *Int J Appl Radiat Isot* 1983; 34:1560-1562.

Okada RD, Elmaleh D, Werre GS, Strauss HW. Myocardial kinetics of ¹²³I-labeled-16-hexadecanoic acid. *Eur J Nucl Med* 1983; 8:211-217.

Seitz DE, Lee S-H, Hanson RN, Bottaro JC. Synthesis and reactivity of the 2,5-bis(trimethylstannyl) derivatives of thiophene and furan. *Synth Commun* 1983; 13:122-129.

1984

Abrams MJ, Davison A, Faggiani R, Jones AG, Lock CJL. Chemistry and structure of hexakis(thiourea-S)technetium(III) trichloride tetrahydrate, $[\text{Tc}(\text{SC}(\text{NH}_2)_2)_6\text{Cl}_3 \cdot 4\text{H}_2\text{O}$. *Inorg Chem* 1984; 23:3284-3288.

Bloomer WD, McLaughlin WH, Adelstein SJ, Wolf AP. Therapeutic applications of Auger and alpha emitting radionuclides. *Strahlentherapie* 1984; 160:755-757.

Bloomer WD, McLaughlin WH, Lambrecht RM, Atcher RW, Mirzadeh S, Madara JL, Milius RA, Zalutsky MR, Adelstein SJ, Wolf AP. ²¹¹At radiocolloid therapy: Further observations and comparison with radiocolloids of ³²P, ¹⁶⁵Dy, and ⁹⁰Y. *Int J Radiat Oncol Biol Phys* 1984; 10:341-348.

Brenner D, Davison A, Lister-James J, Jones AG. The synthesis and characterization of a series of isomeric oxotechnetium(+5) bisimido bisthiolates. *Inorg Chem* 1984; 23:3793-3797.

Franke LA, Hanson RN. Radioiodinated ligands for the estrogen receptor: Effect of 3-*o*-methylation on tissue distribution. *J Nucl Med* 1984; 25:1116-1121.

Goodman MM, Knapp FF Jr, Elmaleh DR, Strauss HW. New myocardial imaging agents: Synthesis of 15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid by decomposition of a 3,3-(1,5-pentanediyl)triazene precursor. *J Org Chem* 1984; 49:2322-2325.

Hanson RN. Selenium-sulfur analogs 7. Synthesis and characterization of 4-aralkyl-1,3-selenazoles and -1,3-thiazoles. *J Heterocycl Chem* 1984; 21:57-59.

Hanson RN, El-Shourbagy T, Hassan M. Radioiodinated 1-substituted 4-phenyl piperazines as potential brain imaging agents. *J Labelled Compd Radiopharm* 1984; 21:1082-1083.

Hanson RN, Franke LA. Preparation and evaluation of 17 α -[I-125]iodovinyl-11-methoxyestradiol as a highly selective radioligand for tissues containing estrogen receptors: Concise communication. *J Nucl Med* 1984; 25:998-1002.

Hanson RN, Franke LA. Electrophilic destannylation: A versatile and efficient method for radiohalogenation. *J Labelled Compd Radiopharm* 1984; 21:1102-1103.

Hanson RN, Franke LA, Kaplan ML. Preparation and evaluation of 17 α -[I-125]vinlyestradiol derivatives as estrogen receptor-seeking agents. *J Labelled Compd Radiopharm* 1984; 21:1172-1173.

Hanson RN, Seitz DE, Bottaro JC. Radiohaloestannylation: Synthesis of ¹²⁵I-labeled 17 α -E-

iodovinylestradiol. *Int J Appl Radiat Isot* 1984; 35:810-812.

Holman BL, Jones AG, Lister-James J, Davison A, Abrams MJ, Kirshenbaum JM, Tumeh SS, English RJ. A new myocardial imaging agent, Tc-99m-labeled hexakis(t-butylisonitrile)-technetium(I) [Tc-99m-TBI]: Initial experience in the human. *J Nucl Med* 1984; 25:1350-1355.

Hurwitz RA, Treves S, Kuruc A. Right ventricular and left ventricular ejection fraction in pediatric patients with normal hearts: First pass radionuclide angiography. *Am Heart J* 1984; 107:726-732.

Jones AG, Abrams MJ, Davison A, Brodack JW, Toothaker AK, Adelstein SJ, Kassis AI. Biological studies of a new class of technetium complexes: The hexakis(alkylisonitrile)-technetium(I) cations. *Int J Nucl Med Biol* 1984; 11:225-234.

Kearfott KJ, Elmaleh DR, Goodman M, Correia JA, Alpert NM, Ackerman RH, Brownell GL, Strauss HW. Comparison of 2- and 3-¹⁸F-fluoro-deoxy-D-glucose for studies of tissue metabolism. *Int J Nucl Med Biol* 1984; 11:15-22.

Kuruc A, Treves S, Smith W, Fujii A. An automated algorithm for radionuclide angiographic quantitation of circulatory shunting. *Comput Biomed Res* 1984; 17:481-493.

Packard AB, Treves S, O'Brien GM, Knapp FF Jr, Butler TA. Chemical and physical parameters affecting the performance of the Os-191/Ir-191m generator. In: Knapp FF Jr, Butler TA, eds. *Radionuclide Generators: New Systems for Nuclear Medicine Applications*. Washington, DC: ACS Symposium Series #241, 1984:51-66.

Sodoyez JC, Sodoyez-Goffaux F, Treves S, Kahn CR, von Frenckell R. In vivo imaging and quantitative analysis of insulin-receptor interaction in lean and obese Zucker rats. *Diabetologia* 1984; 26:229-233.

1985

Davison A, DePamphilis BV, Faggiani R, Jones AG, Lock CJL, Orvig C. The preparation, characterization, and crystal and molecular structure of oxobis(ethan-1,2-dithiolato-(S- μ S')technetium(V)oxo(ethan-1,2-dithiolato-S-S')technetium(V): (TcO)₂(SCH₂CH₂S)₃. A technetium(V) compound containing metal-sulfur-metal bridges. *Can J Chem* 1985; 63:319-323.

Elmaleh DR, Livni E, Okada RD, Needham F-L, Schleuederberg J, Strauss HW. The synthesis and evaluation of radioiodinated 14-(iodophenyl)-3-(R,S)methyltetradecanoic acid. *Nucl Med Commun* 1985; 6:287-297.

Goodman MM, Callahan AP, Knapp FF Jr, Strauss H, Elmaleh D, Richards P, Mausner LF. New myocardial imaging agents: Preparation of 15-(p-[¹²³I]iodophenyl)-6-tellurapentadecanoic acid from sodium ¹²³I-iodide by a triazene decomposition reaction. In: Paras P, Thiessen JW, eds. *The Developing Role of Short-lived Radionuclides in Nuclear Medical Practice, Proceedings of a symposium*, Washington DC, May 1983, DOE Symposium Series 56. Oak Ridge: Oak Ridge Associated Universities, 1985:488-498.

Hanson RN. Radioiodinated 1-substituted-4-phenylpiperazines as potential brain imaging agents. *Int J Nucl Med Biol* 1985; 12:315-320.

Hanson RN, Franke LA, Webb N. Radioiodinated 1-(diethylaminopropyl)-4-phenylpiperazine: A

potential brain imaging agent. *Int J Nucl Med Biol* 1985; 12:397-400.

Hanson RN, Hariharan S, Astik R. Synthesis of 4-(4-iodophenyl)piperazine and the 1-carboxamidino derivative. *J Heterocycl Chem* 1985; 22:47-48.

Hanson RN, Jones GS, Franke L, Kizuka H, Elmaleh DR. Preparation and evaluation of 3-[¹²⁵I]iodo-4-aminophentermine as a brain perfusion imaging agent: Comparison with labeled phentermine derivatives. *Int J Nucl Med Biol* 1985; 12:321-325.

Heller GV, Parker JA, Packard AB, Treves ST, Kuruc AR, Smith WA, Cronan DP, O'Brien GM, Kolodny GM. Potential for iridium-191m first-pass radionuclide angiocardiography for the evaluation of left ventricular function in adults: A comparison with gated-equilibrium radionuclide angiocardiography. In: Paras P, Thiessen JW, eds. Single-photon Ultrashort-lived Radionuclides, Proceedings of symposium, May 1983, Washington, DC, DOE Symposium Series 57, CONF-830504. Oak Ridge: Oak Ridge Associated Universities, 1985:45-53.

Jones AG. Designing tracers for in vivo studies: Non-cyclotron tracers. In: Feindel W, Frackowiak RSJ, Gadian D, Magistretti PL, Zalutsky MR, eds. Discussions in Neurosciences. Brain Metabolism and Imaging: Report of the 1984 FESN Study Group, Vol II(2). Geneva: Fondation pour l'Etude du Systeme Nerveux et Peripherique (FESN), 1985:94-97.

Kizuka H, Elmaleh DR, Brownell GL, Strauss HW, Hanson RN. Synthesis and evaluation of p-iodophentermine (IP) as a brain perfusion imaging agent. *Nucl Med Commun* 1985; 6:49-56.

Knapp FF Jr, Goodman MM, Elmaleh DR, Okada R, Strauss HW. Development of radioiodinated fatty acids for applications in nuclear cardiology. In: Paras P, Thiessen JW, eds. The Developing Role of Short-lived Radionuclides in Nuclear Medical Practice, Proceedings of symposium, Washington DC, May 1983, DOE Symposium Series 56. Oak Ridge: Oak Ridge Associated Universities, 1985:289-311.

Livni E, Elmaleh DR, Barlai-Kovach MM, Goodman MM, Knapp FF Jr, Strauss HW. Radioiodinated beta-methyl phenyl fatty acids as potential tracers for myocardial imaging and metabolism. *Eur Heart J* 1985; 6(suppl B):85-90.

Miller DD, Elmaleh DR, McKusick KA, Boucher CA, Callahan PJ, Strauss HW. Radiopharmaceuticals for cardiac imaging. *Radiol Clin North Am* 1985; 23:765-781.

Neumeyer JL, Guan J-H, Niznik HB, Dumbrille-Ross A, Seeman P, Padmanabhan S, Elmaleh DR. Novel photoaffinity label for the dopamine D₂ receptor: Synthesis of 4-amino-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide (iodoazidoclebopride, IAC) and the corresponding ¹²⁵I-labeled analog (¹²⁵IAC). *J Med Chem* 1985; 28:405-407.

Packard AB, O'Brien GM, Treves S. Osmium-191-iridium-191m generator design. In: Paras P, Thiessen JW, eds. Single-photon Ultrashort-lived Radionuclides, Proceedings of symposium, May 1983, Washington, DC, DOE Symposium Series 57, CONF-830504. Oak Ridge: Oak Ridge Associated Universities, 1985:244-249.

Packard AB, O'Brien GM, Treves S. ¹⁹²Ir concentration in the eluate of the ¹⁹¹Os--^{191m}Ir generator: Technical note. *Int J Appl Radiat Isot* 1985; 36:164.

Sodoyez J-C, Sodoyez-Goffaux F, von Frenckell R, DeVos CJ, Treves S, Kahn CR. Differing effects of antiinsulin serum and antiinsulin receptor serum on ¹²³I-insulin metabolism in rats. *J Clin Invest* 1985; 75:1455-1462.

Strauss HW, Gold HK, Alpert NM, McKusick KA, Elmaleh D, Treves S. Continuous evaluation of coronary flow with iridium-191m. In: Paras P, Thiessen JW, eds. Single-photon Ultrashort-lived Radionuclides, Proceedings of symposium, May 1983, Washington, DC, DOE Symposium Series 57, CONF-830504. Oak Ridge: Oak Ridge Associated Universities, 1985:97-101.

Treves S, Packard A, Kuruc A, O'Brien G. Iridium-191m angiography: Diagnosis and quantitation of shunts and evaluation of cardiac function. In: Paras P, Thiessen JW, eds. Single-photon Ultrashort-lived Radionuclides, Proceedings of symposium, May 1983, Washington, DC, DOE Symposium Series 57, CONF-830504. Oak Ridge: Oak Ridge Associated Universities, 1985:10-18.

Yonekura Y, Brill AB, Som P, Yamamoto K, Srivastava SC, Iwai J, Elmaleh DR, Livni E, Strauss HW, Goodman MM, Knapp FF Jr. Regional myocardial substrate uptake in hypertensive rats: A quantitative autoradiographic measurement. *Science* 1985; 227:1494-1496.

1986

Angelberger P, Dudczak R, Jones AG, Lister-James J, Wagner-Loffler M, Buchheit O, Fally F. Tc-99m-hexakis(t-butylisonitrile)technetium(I) (Tc-99m-TBI): Optimized synthesis, radiochromatography, biodistribution and preliminary clinical studies. In: Nicolini M, Bandoli G, Mazzi U, eds. *Technetium in Chemistry and Nuclear Medicine 2*. Verona: Cortina International, 1986:177-186.

Bianco JA, Elmaleh DR, Lepo JA, King MA, Moring A, Livni E, Espinoza E, Alpert JS, Strauss HW. Effect of glucose and insulin infusion on the myocardial extraction of a radioiodinated methyl-substituted fatty acid. *Eur J Nucl Med* 1986; 12:120-124.

Campbell S, Holman BL, Kirshenbaum JM, Antman EM, Lister-James J, Davison A, Koslowski J, English RJ, Jones AG. The scintigraphic evaluation of myocardial infarction and regional ventricular performance using technetium-99m hexakis(t-butylisonitrile)technetium(I) (TBI): A new myocardial imaging agent. *Eur J Nucl Med* 1986; 12:219-225.

Carroll TR, Davison A, Jones AG. Ligand exchange in the synthesis of technetium complexes at carrier added and no carrier added concentrations. In: Nicolini M, Bandoli G, Mazzi U, eds. *Technetium in Chemistry and Nuclear Medicine 2*. Verona: Cortina International, 1986:169-170.

Elmaleh DR, Padmanabhan S, Niznik HB, Seeman P, Guan J-H, Neumeyer JL. In vivo evaluation of ¹²³I labeled iodoclebopride. In: Fisher A, ed. *Alzheimer's and Parkinson's Diseases*. London: Plenum Publishing Company, 1986:645-653.

Elmaleh DR, Padmanabhan S, Livni E, Hassan MA, Kizuka H, Correia JA, Hanson RN, Strauss HW. Synthesis and evaluation of some [11C]-4-aryl piperazinium salts as myocardial imaging agents. In: *Medical Applications of Cyclotrons IV*. Turku: 1986:359.

English RJ, Lister-James J, Jones AG, Davison A, Holman BL. Imaging with a new ^{99m}Tc-labeled myocardial perfusion agent: ^{99m}Tc-TBI. *J Nucl Med Technol* 1986; 14:6-10.

Holman BL, Campbell CI, Lister-James J, Jones AG, Davison A, Kloner RA. Effect of reperfusion and hyperemia on the biodistribution in dogs of the myocardial imaging agent ^{99m}Tc-TBI. *J Nucl Med* 1986; 27:1172-1177.

Kassis AI, Venkateshan CN, Layne WW, Eisenbarth G, Kaldany A, Kinsey BM, Adelstein SJ. Iodinated monoclonal antibody internalization by tumor cells. *J Labelled Compd Radiopharm* 1986; 23:1299-1300.

Kinsey BM, Kassis AI, Layne WW, Adelstein SJ. Efficient conjugation of DTPA to monoclonal antibodies in biological fluids for use in radiolabeling. *J Labelled Compd Radiopharm* 1986; 23:1287.

Kizuka H, Elmaleh DR. Preparation of N-[¹¹C-methyl]chlorphentermine (¹¹C-NMCP) through methylation of chlorphentermine trifluoroacetamide. *J Labelled Compd Radiopharm* 1986; 23:1068-1069.

Kizuka H, Elmaleh DR, Boudreaux GJ, Strauss HW, Ackerman RH, Brownell GL. N-[¹¹C-methyl]chlorphentermine and N,N-[¹¹C-dimethyl]chlorphentermine as brain blood-flow agents for positron emission tomography. *J Nucl Med* 1986; 27:532-537.

Livni E, Spellman JP, Correia JA, Alpert NM, Brownell GL, Strauss HL, Elmaleh DR. [¹¹C]MPTP: A potential tracer for Parkinson's disease research in laboratory animals. *J Nucl Med* 1986; 27:1600-1603.

Miller DD, Elmaleh DR, McKusick KA, Boucher CA, Callahan RJ, Strauss HW. Radiopharmaceuticals for cardiac imaging. *Radiol Clin North Am* 1986; 23:765-781.

Miller DD, Gill JB, Fischman AJ, Callahan RJ, Elmaleh DR, Boucher CA, Strauss HW. New radionuclides for cardiac imaging. *Prog Cardiovasc Dis* 1986; 28:419-434.

Packard AB, O'Brien GM, Treves S. The current status of the Os-191-Ir-191m generator. In: Cox PH, Mather SJ, Sampson CB, Lazarus CR, eds. *Progress in Radiopharmacy*. Dordrecht: Martinus Nijhoff Publishers, 1986:21-31.

Patterson GS, Davison A, Jones AG, Costello CE, Maleknia SD. Synthesis and characterization of tris(beta-diketonato)technetium(III) and -(IV) complexes. *Inorg Chim Acta* 1986; 114:141-144.

Sia STB, Holman BL, McKusick K, Rigo P, Gillis F, Sporn V, Perez-Balino N, Mitta A, Vosberg H, Szabo Z, Schwartzkopff B, Moretti J-L, Davison A, Lister-James J, Jones AG. The utilization of Tc-99m-TBI as a myocardial perfusion agent in exercise studies: Comparison with Tl-201 thallous chloride and examination of its distribution in humans. *Eur J Nucl Med* 1986; 12:333-336.

Strauss HW, Gill J, Miller DD, Callahan R, Elmaleh D. Medical concerns in the application of ultrashort-lived radiopharmaceuticals. In: Schlafke-Stelson AT, Watson EE, ed. *Proceedings Fourth International Radiopharmaceutical Dosimetry Symposium*, Oak Ridge, Tennessee, November 1985, CONF-85113 (DE86010102). Oak Ridge: Oak Ridge Associated Universities, 86:186-193.

Yamamoto K, Som P, Brill AB, Yonekura Y, Srivastava SC, Meinken GE, Iwai J, Goodman MM, Knapp FF Jr, Elmaleh DR, Livni E, Strauss HW. Dual tracer autoradiographic study of β -methyl-(1-¹⁴C)-heptadecanoic acid and 15-p-(¹³¹I)iodophenyl- β -methylpentadecanoic acid in normotensive and hypertensive rats. *J Nucl Med* 1986; 27:1178-1183.

radionuclides. *Nucl Med Biol* 1987; 14:165-169.

Davison A, DePamphilis BV, Franklin KJ, Jones AG, Lock CJL. Synthesis and characterization of complexes containing the bis(1,2-diolato)oxotechnetium core. *Inorg Chim Acta* 1987; 128:161-167.

Elmaleh DR, Kizuka H, Tu Y-K, Buonanno FS, Strauss HW, Brownell GL, Alpert NM, Correia JA, Ackerman RH. Phentermine analogs as improved brain blood flow tracers. *J Cereb Blood Flow Metab* 1987; 7(suppl 1):S572.

Elmaleh DR, Livni E, Strauss HW, Miller DD, van der Wall EE. Radiopharmaceuticals for cardiovascular nuclear medicine. In: *Noninvasive Imaging of Cardiac Metabolism*. Dordrecht: Martinus Nijhoff Publishers, 1987:1-39.

Hachiya HL, Treves ST, Kahn CR, Sodoyez J-C, Sodoyez-Goffaux F. Altered insulin distribution and metabolism in type I diabetics assessed by [¹²³I]-insulin scanning. *J Clin Endocrinol Metab* 1987; 64:801-808.

Hanson RN, Hassan M. Phenylpiperazine based radiopharmaceuticals for brain imaging: Synthesis and evaluation of radioiodinated 1-alkyl-4-phenylpiperazines. *J Med Chem* 1987; 30:29-34.

Holman BL, Sporn V, Jones AG, Sia STB, Perez-Balino N, Davison A, Lister-James J, Kronauge JF, Mitta AEA, Camin LL, Campbell S, Williams SJ, Carpenter AT. Myocardial imaging with technetium-99m CPI: Initial experience in the human. *J Nucl Med* 1987; 28:13-18.

Lauffer RB, Vincent AC, Padmanabhan S, Villringer A, Saini S, Elmaleh DR, Brady TJ. Hepatobiliary MR contrast agents: 5-Substituted iron-EHMG derivatives. *Magn Reson Med* 1987; 4:582-590.

Layne WW, Kassis AI, Van den Abbeele A, Kinsey BM, Adelstein SJ. HPLC analysis of the dissociation and recombination of rabbit immunoglobulin G. *J Immunol Methods* 1987; 96:195-199.

Packard AB, Treves ST, O'Brien GM, Lim KS. An osmium-191/iridium-191m radionuclide generator using an oxalato osmate parent compound. *J Nucl Med* 1987; 28:1571-1576.

Sia STB, Holman BL, Campbell S, Lister-James J, English RJ, Kronauge JF, Davison A, Jones AG. The utilization of technetium-99m CPI as a myocardial perfusion imaging agent in exercise studies. *Clin Nucl Med* 1987; 12:681-687.

Summerville DA, Packard AB, Bartynski B, Lim KS, Chervu LR, Treves ST. Evaluation of the renal clearance of technetium-99m PAHIDA in dogs. *J Nucl Med* 1987; 28:907-909.

1988

Adelstein SJ, Kassis AI. Criteria for the selection of nuclides for radioimmunotherapy. In: Srivastava SC, ed. *Radiolabeled Monoclonal Antibodies for Imaging and Therapy, Proceedings of the NATO Advanced Study Institute on Radiolabeled Monoclonal Antibodies for Imaging and Therapy: Potential, Problems and Prospects*, Castelvecchio Pascoli, Italy, July 20-August 1, 1986. New York: Plenum Publishing Corporation, 1988:165-176.

Bryson N, Dewan JC, Lister-James J, Jones AG, Davison A. Neutral technetium(V) complexes with amide-thiol-thioether chelating ligands. *Inorg Chem* 1988; 27:2154-2161.

Davison A, Kronauge JF, Jones AG, Pearlstein RM, Thornback JR. ⁹⁹Tc NMR spectroscopy of technetium(I) phosphine and phosphite complexes. *Inorg Chem* 1988; 27:3245-3246.

de Vries N, Dewan JC, Jones AG, Davison A. Complexes of technetium(III) with sterically hindered arenethiolates and their interactions with small pi-accepting molecules. *Inorg Chem* 1988; 27:1574-1580.

Jones GS, Livni E, Strauss HW, Elmaleh DR. Synthesis and biological evaluation of 1-[¹¹C]3,3-dimethylphenylheptadecanoic acid. *J Nucl Med* 1988; 29:68-72.

Kairento A-L, Livni E, Mattila S, Harjula A, Porkka L, Lindroth L, Elmaleh DR. Comparative evaluation of ¹²³I-(14-p-iodophenyl)-betamethyl tetradecanoic acid and ²⁰¹Tl in the detection of infarcted areas on the dog heart using SPECT. *Nucl Med Biol* 1988; 15:333-338.

Kinsey BM, Macklis RM, Ferrara JM, Layne WW, Burakoff SJ, Kassis AI. Efficient conjugation of DTPA to monoclonal antibodies in biological fluids for use in radiolabeling. *Nucl Med Biol* 1988; 15:285-292.

Livni E, Elmaleh DR. Synthesis of 16-[¹⁸F]fluoro-betamethyl-hexadecanoic acid ([¹⁸F]FBMHA) and 16-[¹⁸F]fluorohexadecanoic acid ([¹⁸F]FHA) from the corresponding triflates. In: *Proceedings of the Seventh International Symposium on Radiopharmaceutical Chemistry*, Groningen, The Netherlands, July 1988. Groningen: University of Groningen, 1988:231-232.

Macklis RM, Kaplan WD, Ferrara JM, Kinsey BM, Kassis AI, Burakoff SJ (1988). Biodistribution studies of anti-Thy 1.2 immunoconjugates: Implications for radioimmunotherapy. *Int J Radiat Oncol Biol Phys* 1988; 15:383-389.

Macklis RM, Kinsey BM, Kassis AI, Ferrara JLM, Atcher RW, Hines JJ, Coleman CN, Adelstein SJ, Burakoff SJ. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. *Science* 1988; 240:1024-1026.

Miller DD, Gill JB, Livni E, Elmaleh DR, Aretz T, Boucher CA, Strauss HW. Fatty acid analogue accumulation: A marker of myocyte viability in ischemic-reperfused myocardium. *Circ Res* 1988; 63:681-692.

Pearlstein RM, Lock CJL, Faggiani R, Costello CE, Zeng C-H, Jones AG, Davison A. Synthesis and characterization of technetium(V) complexes with amine, alcoholate, and chloride ligands. *Inorg Chem* 1988; 27:2409-2413.

Piwnica-Worms D, Kronauge JF, Holman BL, Lister-James J, Davison A, Jones AG. Hexakis-(carbomethoxyisopropylisonitrile) technetium(I), a new myocardial perfusion imaging agent: Binding characteristics in cultured chick heart cells. *J Nucl Med* 1988; 29:55-61.

Van den Abbeele AD, Aaronson RA, Adelstein SJ, Kassis AI (1988). Does the in vitro testing for immunoreactivity of an antibody reflect its in vivo behavior? *J Nucl Med Allied Sci* 1988; 32:260-267.

1989

Bryson NJ, Brenner D, Lister-James J, Jones AG, Dewan JC, Davison A. Synthesis and molecular structure of a "lantern" dimer, $(\text{AsPh}_4)_2[\text{Tc}_2\text{O}_2(\text{SCH}_2\text{CONHCH}_2\text{CH}_2\text{NHCOCH}_2\text{S})_4]$. *Inorg Chem* 1989; 28:3825-3828.

de Vries N, Davison A, Jones AG. Trigonal bipyramidal compounds of technetium with a tetradeinate "umbrella" ligand. *Inorg Chim Acta* 1989; 165:9-10.

Finkler NJ, Muto MG, Kassis AI, Weadock K, Tumeh SS, Zurawski V Jr, Knapp RC.

Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. *Gynecol Oncol* 1989; 34:339-344.

Fischman AJ, Saito T, Dilsizian V, Rocco TP, Yasuda T, Gonzalez E, Elmaleh DR, Strauss HW. Myocardial fatty acid imaging: Rationale, comparison of ¹¹C- and ¹²³I-labeled fatty acids, and potential clinical utility. *Am J Cardiac Imaging* 1989; 3:288-296.

Khawli LA, Kassis AI. Synthesis of ¹²⁵I labeled N-succinimidyl p-iodobenzoate for use in radio-labeling antibodies. *Nucl Med Biol* 1989; 16:727-733.

Mariani G, Van den Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI. Monoclonal antibody internalization by tumor cells: An experimental model for potential radioimmunotherapy application. *Nucl Med Biol* 1989; 16:147-150.

Mariani G, Van den Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI. Internalization of monoclonal 3G5-IgM by a rat insulinoma cell line. In: Schmidt HAE, Buraggi GL, eds. *Nuclear Medicine: Trends and Possibilities in Nuclear Medicine, Proceedings of European Nuclear Medicine Congress, 1988*. Nuklearmedizin 1989; Suppl 25:602-605.

Morrel EM, Tompkins RG, Fischman AJ, Wilkinson RA, Burke JF, Rubin RH, Strauss HW, Yarmush ML. Autoradiographic method for quantitation of radiolabeled proteins in tissues using indium-111. *J Nucl Med* 1989; 30:1538-1545.

Muto MG, Lepisto EM, Van den Abbeele AD, Kassis AI. The influence of human anti-murine antibody on CA125 levels in ovarian cancer patients undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. *Am J Obstet Gynecol* 1989; 161:1206-1212.

Nicholson T, de Vries N, Davison A, Jones AG. Synthesis, spectroscopy and structural characterization of five-coordinate bis(aryldiazenido) technetium complexes and their protonation reactions. X-ray structure of $[TcCl(PPh_3)_2(NNC_6H_4Br)_2]$. *Inorg Chem* 1989; 28:3813-3819.

O'Connell LA, Pearlstein RM, Davison A, Thornback JR, Kronauge JF, Jones AG. Technetium-99m NMR spectroscopy: Chemical shift trends and long range coupling effects. *Inorg Chim Acta* 1989; 161:39-43.

Packard AB, Srivastava SC, Richards P. Synthesis and biological properties of the lipophilic technetium-99m complex ^{99m}Tc(acac)₃. *Nucl Med Biol* 1989; 16:291-294.

Piwnica-Worms D, Kronauge JF, Holman BL, Davison A, Jones AG. Comparative myocardial uptake characteristics of hexakis(alkylisonitrile)technetium(I) complexes: Effect of lipophilicity. *Invest Radiol* 1989; 24:25-29.

Rubin RH, Fischman AJ, Callahan RJ, Khaw BA, Keech F, Ahmad M, Wilkinson RA, Strauss HW. The utility of ¹¹¹In-labeled nonspecific immunoglobulin scanning in the detection of focal inflammation. *N Engl J Med* 1989; 321:935-940.

Weadock KS, Anderson LL, Kassis AI. A simple remote system for the high-level radioiodination of monoclonal antibodies. *J Nucl Med Allied Sci* 1989; 33:37-41.

Strauss HW, Fischman AJ. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. *J Nucl Med* 1990; 31:2022-2028.

Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, Van den Abbeele AD, Mariani G, Ito S. Potential for tumor therapy with iodine-125 labeled immunoglobulins. *Nucl Med Biol* 1990; 18:43-44.

Baranowska-Kortylewicz J, Berman RM, Kaldany A, Eisenbarth GS, Kassis AI. Immunoradiometric assay for antibodies recognizing antigenic gangliosides. *J Nucl Med Allied Sci* 1990; 34:34-41.

Carter EA, Barlai-Kovach M, Elmaleh DR, Livni E. Acute alcohol ingestion reduces fatty acid extraction of the heart, liver and small intestine. *Alcohol Clin Exp Res* 1990; 14:781-784.

Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. *Cancer Res* 1990; 50:2198-2202.

de Vries N, Costello CE, Jones AG, Davison A. Technetium nitrido complexes with amine and thiolate ligands: Structural characterizations of nitridobis(1,1,2,2-tetramethylguanidine)bis(2,3,5,6-tetramethylbenzenethiolato)technetium, a complex with coordinatively bound 1,1,2,2-tetramethylguanidine. *Inorg Chem* 1990; 29:1348-1352.

de Vries N, Kronauge JF, Davison A, Jones AG. Compounds of technetium(III) with the "umbrella" ligand, tris(α -thiophenylato)phosphine. In: Nicolini M, Bandoli G, Mazzi U, eds. *Technetium and Rhenium in Chemistry and Nuclear Medicine 3*. Verona: Cortina International, 1990:215-220.

Fink GD, Montgomery JA, David F, Garneau M, Livni E, Elmaleh DR, Strauss HW, Brunengraber H. Metabolism of β -methyl-heptadecanoic acid in the perfused rat heart and liver. *J Nucl Med* 1990; 31:1823-1830.

Fischman AJ, Rubin RH, White JA, Locke E, Wilkinson RA, Nedelman M, Callahan RJ, Khaw BA, Strauss HW. Localization of Fc and Fab fragments of nonspecific polyclonal IgG at focal sites of inflammation. *J Nucl Med* 1990; 31:1199-1205.

Leon AS, Verdera ES, Leon ET, Mut F, Oliveira C, Beretta M, Garcia FA, Kronauge JF, Jones AG. $^{99m}\text{Tc(I)}$ hexakis carbometoxiisopropilisonitrilo: Desarrollo de un juego de reactivos liofilizado y estudios radiofarmacológicos. *Rev Esp Med Nuclear* 1990; 9:5-22.

Livni E, Ito S, Kassis AI, Elmaleh DR. ($^3\text{H}/^{14}\text{C}$)Beta-methylheptadecanoic acid subcellular distribution and lipid incorporation in mouse heart. *Lipids* 1990; 25:238-240.

Mariani G, Kassis AI, Adelstein SJ. Antibody internalization by tumor cells: Implications for tumor diagnosis and therapy. *J Nucl Med Allied Sci* 1990; 34:51-55.

Morgan GF, Thornback J, Delmon L, Jones AG, Nicholson T, Davison A. Seven coordinate technetium xanthate complexes: A novel class of compounds with potential in nuclear medicine. In: Schmidt HAE, Buraggi GL, eds. *Nuclear Medicine: Trends and Possibilities in Nuclear Medicine, Proceedings of European Nuclear Medicine Congress, 1989*. Nuklearmedizin 1990; Suppl 26:84-86.

Muto MG, Finkler NJ, Kassis AI, Lepisto EM, Knapp RC. Human anti-murine antibody responses in ovarian cancer patients undergoing radioiummunotherapy with the murine monoclonal antibody OC-125. *Gynecol Oncol* 1990; 38:244-248.

Nicholson T, Davison A, Jones AG. The characterization of technetium organohydrazide chelate complexes. The X-ray crystal structure of $[\text{TcO}(\text{SC}_6\text{H}_2\text{Pr}_3)_2(\text{PhNNCON}_2\text{HPh})]$. *Inorg Chim Acta* 1990; 168:227-231.

Nicholson T, de Vries N, Davison A, Jones AG. Synthesis and characterization of aryldiazenido technetium complexes and their protonation reactions. The X-ray structure of $[\text{TcCl}(\text{PPh}_3)_2(\text{NNC}_6\text{H}_4\text{Br})_2]$. In: Nicolini M, Bandoli G, Mazzi U, eds. *Technetium and Rhenium in Chemistry and Nuclear Medicine 3*. Verona: Cortina International, 1990:96-108.

Nicholson T, Thornback J, Morgan GF, O'Connell L, Davison A, Jones AG. Synthesis and characterization of seven coordinate technetium(III) xanthate complexes. The X-ray structure of $[\text{Tc}(\text{PPh}_3)(\text{S}_2\text{COC}_4\text{H}_9)_3]$. In: Nicolini M, Bandoli G, Mazzi U, eds. *Technetium and Rhenium in Chemistry and Nuclear Medicine 3*. Verona: Cortina International, 1990:207-214.

Nicholson T, Thornback JR, O'Connell L, Morgan G, Davison A, Jones AG. Synthesis, spectroscopy, and structural characterization of neutral seven-coordinate technetium xanthate complexes: The X-ray structure of $[\text{Tc}(\text{PPh}_3)(\text{S}_2\text{COC}_4\text{H}_9)_3]$, a capped octahedral Tc(III) complex. *Inorg Chem* 1990; 29:89-92.

Piwnica-Worms D, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG. Effect of metabolic inhibition on ^{99m}Tc -MIBI uptake in cultured chick heart cells. *J Nucl Med* 1990; 31:464-472.

Van den Abbeele AD, Aaronson RA, Taube RA, Adelstein SJ, Kassis AI. Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor to normal tissue ratios. *J Nucl Med Allied Sci* 1990; 34:94-102.

1991

Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, Van den Abbeele AD, Mariani G, Ito S. Potential for tumor therapy with iodine-125 labeled immunoglobulins. *Nucl Med Biol* 1991; 18:43-44.

Delmon-Moingeon LI, Mahmood A, Davison A, Jones AG. Strategies for labeling monoclonal antibodies and antibody-like molecules with technetium-99m. *J Nucl Biol Med* 1991; 35:47-59.

DiZio JP, Fiaschi R, Davison A, Jones AG, Katzenellenbogen JA. Progestin-rhenium complexes: Metal-labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy. *Bioconjugate Chem* 1991; 2:353-366.

Fischman AJ, Alpert NM, Livni E, Ray S, Sinclair I, Elmaleh DR, Weiss S, Correia JA, Webb D, Liss R, Strauss HW, Rubin RH. Pharmacokinetics of ^{18}F -labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. *J Pharmacol Exp Ther* 1991; 259:1351-1359.

Fischman AJ, Pike MC, Kroon D, Fucello AJ, Rexinger D, tenKate C, Wilkinson R, Rubin RH, Strauss HW. Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs. *J Nucl Med* 1991; 32:483-491.

Fishman JA, Strauss HW, Fischman AJ, Nedelman M, Callahan R, Khaw BA, Rubin RH. Imaging of pneumocystis carinii pneumonia with ^{111}In -labeled nonspecific IgG: An experimental study. *Nucl Med Commun* 1991; 12:175-187.

Herman LW, Elmaleh DR, Fischman AJ, Hanson RN, Strauss HW. The use of pentafluorophenyl derivatives for the ¹⁸F labeling of proteins. *J Labelled Compd Radiopharm* 1991; 30:205-206.

Juweid M, Fischman AJ, Rubin RH, Baum R, Strauss HW. Comparison of ⁹⁹Tcm-labelled monoclonal anti-granulocyte antibody and ¹¹¹In-labelled IgG for the detection of focal sites of infection in rats. *Nucl Med Commun* 1991; 12:637-644.

Kassis AI. Editorial: Optimizing antibodies for use in nuclear medicine. *J Nucl Med* 1991; 32:1751-1753.

Kronauge JF, Davison A, Roseberry AM, Costello CE, Maleknia S, Jones AG. Synthesis and identification of the monocation $Tc(CPI)_6^+$ in $Tc(CNC(CH_3)_2COOCH_3)_6Cl$ and its hydrolysis products. *Inorg Chem* 1991; 30:4265-4271.

Mariani G, Ito S, Nayak RC, Baranowska-Kortylewicz J, Venkateshan CN, Van den Abbeele AD, Eisenbarth GS, Adelstein SJ, Kassis AI. Capping and internalization of a monoclonal antibody-surface antigen complex: A possible mode of interaction of monoclonal antibodies and tumor cells. *J Nucl Biol Med* 1991; 35:111-119.

Nicholson T, Davison A, Jones AG. The synthesis of a technetium(V) phenylimido complex from pertechnetate. The single crystal X-ray structure of $[TcCl_3(NPh)(PPh_3)_2].CH_2Cl_2$. *Inorg Chim Acta* 1991; 187:51-57.

Nishizawa K, Okunieff P, Elmaleh D, McKusick KA, Strauss HW, Suit HD. Blood flow of human soft tissue sarcomas measured by thallium-201 scanning: Prediction of tumor response to radiation. *Int J Radiat Oncol Biol Phys* 1991; 20:593-597.

Packard AB. Synthesis and characterization of a ⁹⁹Tc-porphyrin complex. *J Labelled Compd Radiopharm* 1991; 30:14-15.

Shen X, Hanson RN, Elmaleh DR. Synthesis and evaluation of radioiodinated tetrafluorophenyl-m-iodobenzoate and tetrafluorophenyl-5-iodopentenoates as conjugating agents for proteins and antibodies. *J Labelled Compd Radiopharm* 1991; 30:222-223.

Steichen JD, Weiss MJ, Elmaleh DR, Martuza RL. Enhanced in vitro uptake and retention of ³H-tetraphenylphosphonium by nervous system tumor cells. *J Neurosurg* 1991; 74:116-122.

Strauss HW, Fischman AJ, Khaw BA. Non-tumor applications of radioimmune imaging. *Nucl Med Biol* 1991; 18:127-134.

tenKate CI, Fischman AJ, Rubin RH, Fuccello AJ, Rexinger D, Wilkinson RA, Du L, Khaw BA, Strauss HW. Effect of isoelectric point on biodistribution and inflammation-imaging properties of indium-111 labeled, nonspecific, polyclonal human IgG. *Eur J Nucl Med* 1991; 17:305-309.

Tompkins RG, Fischman AJ, Yarmush ML. Imaging infections with antibodies: A method to localize occult infections. *Chest* 1991; 100(suppl):169S-172S.

Tumeh SS, Carvalho PA, Van den Abbeele AD, Maguire JH, Rauh DA, Neptune M, Kassis AI. Detection of focal infection by ¹¹¹In-human polyclonal IgG. *J Nucl Biol Med* 1991; 35:4-9.

Van den Abbeele AD, Aaronson RA, Daher S, Taube RA, Adelstein SJ, Kassis AI. Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction. *J Nucl Med* 1991; 32:116-122.

1992

Khawli LA, Kassis AI. m-[¹²⁵I]Iodoaniline: A useful reagent for radiolabeling biotin. *Nucl Med Biol* 1992; 19:297-301.

Khawli LA, Van den Abbeele AD, Kassis AI. N-(m-[¹²⁵I]iodophenyl)maleimide: An agent for high yield radiolabeling of antibodies. *Nucl Med Biol* 1992; 19:289-295.

Kronauge JF, Chiu ML, Cone JS, Davison A, Holman BL, Jones AG, Piwnica-Worms D. Comparison of neutral and cationic myocardial perfusion agents: Characteristics of accumulation in cultured cells. *Nucl Med Biol* 1992; 19:141-148.

Kronauge JF, Leon AS, Silva Verdera E, Balter HS, Leon ET, Mut F, Oliveira MC, Garcia FA, Holman BL, Davison A, Jones AG. Human pharmacokinetics and radiopharmacological studies of the myocardial perfusion agent: Technetium (2-carbomethoxy-2-isocyano-propane). *J Nucl Med* 1992; 33:1949-1957.

Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR Jr, Weadock K, Tumeh SS, Lavin P, Knapp RC. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. *Gynecol Oncol* 1992; 45:265-272.

Nicholson T, Storm SL, Davis WM, Davison A, Jones AG. The synthesis and characterization of [TcCl₃(NPh)(Ph₂PCH₂CH₂PPh₂)] and [TcCl₃(NPh)(PPh₃)]. The single crystal X-ray structure of [TcCl₃(NPh)(Ph₂PCH₂CH₂PPh₂)]. *Inorg Chim Acta* 1992; 196:27-34.

Petersheim M, Moldow RL, Halladay HN, Kastin AJ, Fischman AJ. Conformational studies of N-Tyr-MIF-1 in aqueous solution by ¹H nuclear magnetic resonance spectroscopy. *Int J Pept Protein Res* 1992; 40:41-48.

1993

Babich JW, Graham W, Barrow SA, Dragotakes SC, Tompkins RG, Rubin RH, Fischman AJ. Technetium-99m-labeled chemotactic peptides: Comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. *J Nucl Med* 1993; 34:2176-2181.

Babich JW, Solomon H, Pike MC, Kroon D, Graham W, Abrams MJ, Tompkins RG, Rubin RH, Fischman AJ. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. *J Nucl Med* 1993; 34:1964-1974.

Baranowska-Kortylewicz J, Kassis AI. Labeling of immunoglobulins with bifunctional, sulphydryl-selective, and photoreactive coumarins. *Bioconjugate Chem* 1993; 4:300-304.

Elmaleh DR, Kizuka H, Hanson RN, Jones GS Jr, Herman LW, Strauss HW. Structure-localization relationships of ¹¹C-labeled phentermine derivatives: Effect of aromatic substitution. *Appl Radiat Isot* 1993; 44:821-829.

Elmaleh DR, Padmanabhan S, Hassan MA, Correia JA, Herman LW, Hanson RN, Strauss HW. Synthesis and evaluation of 1-[¹¹C]methyl-4-aryl-piperazinium salts as myocardial imaging agents. *Nucl Med Biol* 1993; 20:427-433.

Fischman AJ, Babich JW, Strauss HW. A ticket to ride: Peptide radiopharmaceuticals. *J Nucl Med*

1993; 34:2253-2263.

Fischman AJ, Rauh D, Solomon H, Babich JW, Tompkins RG, Kroon D, Strauss HW, Rubin RH. In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. *J Nucl Med* 1993; 34:2130-2134.

Kizuka H, Elmaleh DR. Selective monomethylation of the primary amine function using [¹¹C]CH₃I and the N-trifluoroacetyl derivative: Preparation of N-[¹¹C-methyl]chlorphentermine. *Nucl Med Biol* 1993; 20:239-242.

Mahmood A, Delmon-Moingeon LI, Limpa-Amara N, Davison A, Jones AG. A new method for labeling proteins with technetium-99m. *J Labelled Compd Radiopharm* 1993; 32:360-361.

Verdera S, Leon A, Kronauge JF, Leon E, Souto B, Oliver P, Rodriguez A, Tamosiunas G, Esponda A, Jones AG. Radiopharmacological studies of ^{99m}Tc-CPI: Experience with isolated rat atrial tissue. *Nucl Med Biol* 1993; 20:127-132.

Weber DA, Kassis AI. Co-editors preface. Special Supplement of Medical Physics on Radiolabeled Antibody Tumor Dosimetry. *Med Phys* 1993; 20:497.

1994

Elmaleh DR, Livni E, Alpert NM, Strauss HW, Buxton R, Fischman AJ. Myocardial extraction of 1-[¹¹C]betamethylheptadecanoic acid. *J Nucl Med* 1994; 35:496-503.

Fischman AJ, Babich JW, Rubin RH. Infection imaging with technetium-99m-labeled chemotactic peptide analogs. *Semin Nucl Med* 1994; 24:154-168.

Gangopadhyay A, Saravis CA, Kassis AI. Semipreparative isoelectrophoresis of DTPA-conjugated antibody leads to isolation of antibody isoforms with different immunoreactivities. *J Nucl Biol Med* 1994; 38:61-67.

Gangopadhyay A, Van den Abbeele AD, Kassis AI. Modification of mouse IgG isoelectric point following radioiodination. *Antibody Immunoconj Radiophar* 1994; 7:171-178.

Herman LW, Fischman AJ, Tompkins RG, Hanson RN, Byon C, Strauss HW, Elmaleh DR. The use of pentafluorophenyl derivatives for the ¹⁸F labelling of proteins. *Nucl Med Biol* 1994; 21:1005-1010.

Kortylewicz ZP, Baranowska-Kortylewicz J, Adelstein SJ, Carmel AD, Kassis AI. Radiolabeled biotin amides from triazenyl precursors: Synthesis, binding, and in-vivo properties. *J Labelled Compd Radiopharm* 1994; 34:1129-1146.

Mahmood A, Delmon-Moingeon L, Limpa-Amara N, Davison A, Jones AG. A new approach to cell labeling with technetium-99m: Synthesis, cell labeling and in-vitro evaluation of cellular function. *J Labelled Compd Radiopharm* 1994; 35:15-16.

Shoup TM, Fischman AJ, Jaywook S, Babich JW, Strauss HW, Elmaleh DR. Synthesis of fluorine-18-labeled biotin derivatives: Biodistribution and infection localization. *J Nucl Med* 1994; 35:1685-1690.

In Press or Submitted

Delmon-Moingeon LI, Mahmood A, Davison A, Jones AG. A new approach to labeling cells with technetium-99m, Part II: Evaluation of radiolabeled human-lymphocyte immune functions.

Nucl Med Biol (submitted).

Gangopadhyay A, Saravis CA, Van den Abbeele AD, Kassis AI. pI-Dependent isolation of antibody isoforms by semipreparative isoelectric focusing. J Nucl Biol Med (in press).

Mahmood A, Delmon-Moingeon LI, Limpa-Amara N, Davison A, Jones AG. A new approach to labeling cells with technetium-99m, Part I: Preparation of modified polylysine and in-vitro labeling of cells. Nucl Med Biol (submitted).

Mahmood A, Wolff JA, Davison A, Jones AG. Technetium and rhenium complexes of amine amide dithiol ligands: Ligand synthesis and metal complexes. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine 4. Verona, Cortina International (in press).

Appendix

referred.

Reprints of papers (in alphabetical order) supported totally
or in part by DE-FG02-86ER60460 (Formerly DE-AC02-76EV04115)
and not previously submitted